Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
A new study appears to resolve controversy over hep C treatment’s association with mortality risk.
Researchers compared health outcomes among people with HIV, including those with and without hepatitis C.
An analysis conducted in Taiwan analyzed health outcomes over more than a decade.
An honest look at what it feels like to live with advanced liver disease.
Researchers analyzed health data regarding modern hep C treatments specific to New South Wales.
Researchers reached this conclusion after reviewing data on more than 30,000 people.
European and U.S. guidelines recommend that all those with cirrhosis undergo biannual screening for liver cancer.
Phase III study misses statistical threshold, but the immunotherapy appears to show some benefit.
Study in China sees an association with several cancer types, especially gastrointestinal malignancies.
Learning to live well with liver disease, even at it’s worst stages, is possible if you know how to.
Analysis of nearly 34,000 people finds no serious adverse events associated with direct-acting antiviral therapy.
Keytruda showed modest benefits for people with hepatocellular carcinoma, and combining Opdivo with Yervoy improved outcomes.
Scientists have firmly established an association between direct-acting antiviral treatment and a lower risk of liver cancer and death.
Better antiretrovirals have likely mitigated HIV’s effects on the risk of end-stage liver disease and liver cancer in those with hep C.
Stella Armstrong’s journey to a healthier life wasn’t easy.
Between August 2018 and January 2019, the FDA doubled the number of liver cancer treatments.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.